» Articles » PMID: 7678083

Increased Serum Levels of Granulocyte Colony-stimulating Factor After Autologous Bone Marrow or Blood Stem Cell Transplantation

Overview
Journal Exp Hematol
Specialty Hematology
Date 1993 Jan 1
PMID 7678083
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of our study was to evaluate the biologic role of granulocyte colony-stimulating factor (G-CSF) for hematologic reconstitution following autologous bone marrow transplantation (ABSCT). Using a commercially available enzyme-linked immunosorbent assay, serum levels of G-CSF were measured in samples from 48 patients (30 male/18 female) who underwent ABMT or ABSCT. Their median age was 34.5 years (range 16 to 51). Autografting was performed (40 ABMT, 8 ABSCT) in 23 AML, 8 ALL and 17 malignant lymphoma patients. Patients transplanted with blood stem cells had a faster leukocyte and neutrophil recovery compared with the ABMT patients (p < 0.025 and p < 0.05, respectively). During marrow aplasia G-CSF serum levels were elevated in all patients, with a median peak value of 2199 pg/mL (range 453 to 8676 pg/mL). A strong reverse correlation (R = -0.76, p < 0.01) could be demonstrated between G-CSF serum level and white blood count (WBC). An additional increase of G-CSF serum levels on days of fever (> or = 38.5 degrees C) or documented infectious disease was observed. During the early phase of marrow aplasia, the endogenously produced amounts of G-CSF reached concentrations which are used for in vitro stimulation of colony-forming unit granulocyte (CFU-G). The relationship between G-CSF serum level and WBC supports the central role of this circulating hemopoietin following myeloablative treatment and autotransplantation. During periods of higher demand such as fever and infectious complications, endogenous G-CSF production is enhanced.

Citing Articles

A mathematical model for reconstitution of granulopoiesis after high dose chemotherapy with autologous stem cell transplantation.

Ostby I, Rusten L, Kvalheim G, Grottum P J Math Biol. 2003; 47(2):101-36.

PMID: 12883857 DOI: 10.1007/s00285-003-0198-6.


Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations.

Piscitelli S, Reiss W, Figg W, Petros W Clin Pharmacokinet. 1997; 32(5):368-81.

PMID: 9160171 DOI: 10.2165/00003088-199732050-00003.


Interleukin-6 and granulocyte colony-stimulating factor synergistically increase peripheral blood progenitor cells in myelosuppressive mice.

Suzuki H, Okano A, Ejima C, Konishi A, Akiyama Y, Ozawa K Jpn J Cancer Res. 1996; 87(9):938-44.

PMID: 8878456 PMC: 5921208. DOI: 10.1111/j.1349-7006.1996.tb02123.x.


Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation. A prospective randomized study.

Torres Gomez A, Jimenez M, Alvarez M, Rodriguez A, Martin C, Garcia M Ann Hematol. 1995; 71(2):65-70.

PMID: 7544628 DOI: 10.1007/BF01699248.